Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01383
|
|||||
| Drug Name |
Camptothecin
|
|||||
| Synonyms |
camptothecin; Camptothecine; 7689-03-4; (S)-(+)-Camptothecin; Campathecin; d-Camptothecin; (+)-Camptothecine; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; (S)-Camptothecin; Camptothecine (8CI); 20(S)-Camptothecin; Camptothecine (S,+); CHEMBL65; UNII-XT3Z54Z28A; MLS000766223; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; XT3Z54Z28A; CHEBI:27656; VSJKWCGYPAHWDS-FQEVSTJZSA-N; Camptothecin, Camptotheca acuminata; NSC-94600; Camptothecin derivat
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Non-small cell lung cancer [ICD11: 2C25] | Phase 3 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H16N2O4
|
|||||
| Canonical SMILES |
CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
|
|||||
| InChI |
InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1
|
|||||
| InChIKey |
VSJKWCGYPAHWDS-FQEVSTJZSA-N
|
|||||
| CAS Number |
CAS 2086-83-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 348.4 | Topological Polar Surface Area | 79.7 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
5009
, 399733
, 597746
, 842008
, 925175
, 3140967
, 7887296
, 7978848
, 8139651
, 8150064
, 8167780
, 10321203
, 11111011
, 11112910
, 11113913
, 11120280
, 11120768
, 11121256
, 11336001
, 11341983
, 11361240
, 11362166
, 11363193
, 11365755
, 11368317
, 11372185
, 11374175
, 11376479
, 11377982
, 11446457
, 11462212
, 11466228
, 11467348
, 11484482
, 11485816
, 11487568
, 11488719
, 11491018
, 11492553
, 11494113
, 11537709
, 14827597
, 14900711
, 17404904
, 24278352
, 26612343
, 26680346
, 26732559
, 26747153
, 26747154
|
|||||
| ChEBI ID |
ChEBI:16118
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [3] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [4] | ||
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00826644) Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient | |||||
| 2 | The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 Jan;24(1):146-9. | |||||
| 3 | Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67. | |||||
| 4 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.